Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRX-07034
- Development stage
- Unknown
- Lead developer
- Epix Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral[4]
01
Overview
PRX-07034 is a potent and highly selective small-molecule antagonist of the serotonin 6 (5-HT6) receptor. It was developed primarily for the treatment of cognitive impairment associated with Alzheimer's disease and schizophrenia, as well as for obesity. Preclinical studies have shown that it enhances working memory and cognitive flexibility in animal models, likely through modulation of both acetylcholine and glutamate neurotransmitter systems. The drug demonstrates high selectivity for the 5-HT6 receptor (Ki = 4–8 nM; IC50 = 19 nM), with over 100-fold selectivity compared to most other GPCRs except D3 and 5-HT1B receptors[1][2][5]. Development was originally by Epix Pharmaceuticals.
- Other names
- PRX 07034PRX07034PRX-07034PRX-07034 hydrochloridePRX07034 hydrochloridePRX 07034 hydrochloride
02
Targets
DRD3 (Dopamine receptor D3)HTR6 (5-hydroxytryptamine receptor 6)MOR (Mu opioid receptor)HRH2 (Histamine H2 Receptor)
Beyond the preview
Go deeper on PRX-07034.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRX-07034.